(MRAD)3 () (1.0622-1.0918) per μg/m3 () () 10 μg/m3 Age: 18-64 years. () () Age: 18-64 years. () Work lost days n/a n/a 0.46% (0.39-0.53%) 1.0471 n/a Recommended (WLD)2 per 1 per 10 CRF: 1.0471 μg/m3 () (1.0397-1.0545) per μg/m3 () () 10 μg/m3 CAFE CBA 2005 () () Age: 15-64 years. Age: 18-64 years. () Acute bronchitis n/a n/a n/a 1.5 (0.91-2.47) per n/a Recommended (incidence, 8-12 14.9 µg/m3 CRF: 1.5 years) () per 14.9 () µg/m3 Annual average. () () Lower respiratory n/a n/a n/a 1.33 (1.11-1.58) per n/a Recommended symptoms 15 µg/m3 CRF: 1.33 () per 15 µg/m3 () () Age: 7-14 years. () Acute respiratory n/a n/a n/a n/a n/a No CRF symptoms recommended. Wheeze No effect. n/a n/a Only for n/a No CRF Rodriguez 2007 American children recommended. Age: 0-5 years. () Perth. () No effect in 1-hour maximum. Australian 6-cities
(MRAD)3 () () Age: 18-64 years. μg/m3 () () Age: 18-64 years. (1.0622-1.0918) per 10 μg/m3 () () Work lost days (WLD)2 n/a n/a 0.46% (0.39-0.53%) per 1 μg/m3 () () CAFE CBA 2005 Age: 15-64 years. 1.0471 per 10 μg/m3 () () Age: 18-64 years. n/a Recommended CRF: 1.0471 (1.0397-1.0545) per 10 μg/m3 () () Acute bronchitis (incidence, 8-12 years) n/a n/a n/a 1.5 (0.91-2.47) per 14.9 µg/m3 () () Annual average. n/a Recommended CRF: 1.5 per 14.9 µg/m3 () () Lower respiratory symptoms n/a n/a n/a 1.33 (1.11-1.58) per 15 µg/m3 () () Age: 7-14 years. n/a Recommended CRF: 1.33 per 15 µg/m3 () () Acute respiratory symptoms n/a n/a n/a n/a n/a No CRF recommended. Wheeze No effect. Rodriguez 2007 Age: 0-5 years. Perth. 1-hour maximum. n/a n/a Only for children () () n/a No CRF recommended. No effect in Australian 6-cities American
health-report.docx